|
EIF4ENIF1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.99952999999642E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.022020E-04 |
| Normal-vs-Stage2 |
1.652020E-02 |
| Normal-vs-Stage3 |
8.10560000000793E-05 |
| Normal-vs-Stage4 |
4.9881999999446E-06 |
| Stage1-vs-Stage2 |
6.604200E-01 |
| Stage1-vs-Stage3 |
4.875600E-01 |
| Stage1-vs-Stage4 |
6.005700E-02 |
| Stage2-vs-Stage3 |
4.016600E-01 |
| Stage2-vs-Stage4 |
8.756200E-02 |
| Stage3-vs-Stage4 |
2.096600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.00669999999015E-05 |
| Normal-vs-AfricanAmerican |
1.907810E-02 |
| Normal-vs-Asian |
1.394060E-02 |
| Caucasian-vs-AfricanAmerican |
9.181000E-01 |
| Caucasian-vs-Asian |
4.507000E-01 |
| AfricanAmerican-vs-Asian |
7.173400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.224400E-04 |
| Normal-vs-Female |
2.08509999999329E-05 |
| Male-vs-Female |
9.335400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.979090E-04 |
| Normal-vs-Age(41-60Yrs) |
1.612530E-04 |
| Normal-vs-Age(61-80Yrs) |
1.020930E-04 |
| Normal-vs-Age(81-100Yrs) |
2.806000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.845000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.018000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.732000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.091000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.902200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.166600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.911640E-01 |
| Classical-VS-Follicular |
9.181600E-03 |
| Classical-VS-Other |
5.642600E-01 |
| Classical-VS-Normal |
5.208200E-04 |
| Tall-VS-Follicular |
6.076200E-01 |
| Tall-VS-Other |
8.841600E-01 |
| Tall-VS-Normal |
1.058230E-03 |
| Follicular-VS-Other |
9.404200E-01 |
| Follicular-VS-Normal |
1.74596999999999E-05 |
| Other-VS-Normal |
5.475800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.357380E-04 |
| Normal-vs-N1 |
1.54266999999875E-05 |
| N0-vs-N1 |
9.756500E-02 |
|
|
